3rd Annual U.S.-CHINA PHARMA™
Shrewd Strategies for Mining Profits from Pharma Opportunities in China
The engine driving healthcare expenditures in China is not only revving faster, it's speeding down the track. According to the latest report by McKinsey & Company, the Chinese market has already doubled, from $156 billion in 2006 to $357 billion in 2011. With market expectations for China's healthcare expenditures to top $1 trillion by 2020, it's no wonder U.S. pharma companies want to be in the driver's seat.
But the healthcare market in China cannot be steered in the direction of major profits by merely copying market strategies used in the U.S and elsewhere abroad. Indeed, it cannot be driven at all because the engine driving it is not for racing but for mining and the key to mining profits is knowing where and how to dig.